# Professor Aswath Damodaran's research on pharmaceutical companies is cited

1 Faculty News August 26, 2015 ![Wall Street Journal logo](/sites/default/files/styles/246w/public/assets/images/wsjlogo.jpg?itok=5Qt0z3WX)>

Excerpt from [The Wall Street Journal](http://www.wsj.com/articles/a-healthy-side-of-insurer-mega-mergers-1440628597) -- "The other great problem is the ability of pharmaceutical and biotechnology companies to charge whatever the market will bear. According to a January 2015 analysis by [Aswath Damodaran](http://www.stern.nyu.edu/faculty/bio/aswath-damodaran), a professor at New York University’s Stern School of Business, the average yearly profit margin for the top 151 pharmaceutical companies world-wide is more than 24% and for the top 400 biotech firms it is nearly 23%."

[Read more](http://www.wsj.com/articles/a-healthy-side-of-insurer-mega-mergers-1440628597)